Phage Therapy as a Novel Strategy in the Treatment of Urinary Tract Infections Caused by E. Coli
Open Access
- 5 June 2020
- journal article
- review article
- Published by MDPI AG in Antibiotics
- Vol. 9 (6), 304
- https://doi.org/10.3390/antibiotics9060304
Abstract
Urinary tract infections (UTIs) are regarded as one of the most common bacterial infections affecting millions of people, in all age groups, annually in the world. The major causative agent of complicated and uncomplicated UTIs are uropathogenic E. coli strains (UPECs). Huge problems with infections of this type are their chronicity and periodic recurrences. Other disadvantages that are associated with UTIs are accompanying complications and high costs of health care, systematically increasing resistance of uropathogens to routinely used antibiotics, as well as biofilm formation by them. This creates the need to develop new approaches for the prevention and treatment of UTIs, among which phage therapy has a dominant potential to eliminate uropathogens within urinary tract. Due to the growing interest in such therapy in the last decade, the bacteriophages (natural, genetically modified, engineered, or combined with antibiotics or disinfectants) represent an innovative antimicrobial alternative and a strategy for managing the resistance of uropathogenic microorganisms and controlling UTIs.Keywords
This publication has 138 references indexed in Scilit:
- Lysogenic Conversion and Phage Resistance Development in Phage Exposed Escherichia coli BiofilmsViruses, 2013
- Host–pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenicEscherichia colibladder infectionFEMS Microbiology Reviews, 2012
- Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strainJournal of Antimicrobial Chemotherapy, 2010
- The K5 Lyase KflA Combines a Viral Tail Spike Structure with a Bacterial Polysaccharide Lyase MechanismPublished by Elsevier BV ,2010
- Persistence of Uropathogenic Escherichia coli in the Face of Multiple AntibioticsAntimicrobial Agents and Chemotherapy, 2010
- Restricting ciprofloxacin-induced resistant variant formation in biofilm of Klebsiella pneumoniae B5055 by complementary bacteriophage treatmentJournal of Antimicrobial Chemotherapy, 2009
- Origins and virulence mechanisms of uropathogenic Escherichia coliExperimental and Molecular Pathology, 2008
- Dispersing biofilms with engineered enzymatic bacteriophageProceedings of the National Academy of Sciences of the United States of America, 2007
- Efficacy of Bacteriophage Therapy against Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in MiceAntimicrobial Agents and Chemotherapy, 2007
- Pathogenic Escherichia coliNature Reviews Microbiology, 2004